The comeback kid: TYSABRI now FDA approved for Crohn disease

Journal of Clinical Investigation

Volumn 118, Issue 3, 2008, Pages 825-826

  Honey, Karen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; BETA1 INTEGRIN; BETA7 INTEGRIN; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG PROTEIN BINDING; FOOD AND DRUG ADMINISTRATION; HUMAN; MULTIPLE SCLEROSIS; NOTE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL; RELAPSE;

ANTIBODIES, MONOCLONAL; CELL MIGRATION INHIBITION; CROHN DISEASE; DRUG APPROVAL; HUMANS; MULTIPLE SCLEROSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 40549083703     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35179     Document Type: Note

References (6)

1. Polman, C.H., et al. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899-910.
2. Langer-Gould, A., Atlas, S.W., Green, A.J., Bollen, A.W., and Pelletier, D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375-381.
3. Van Assche, G., et al. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353:362-368.
4. US FDA. 2005. Natalizumab (marketed as Tysabri) information. http://www.fda.gov/cder/drug/infopage/natalizumab/default.htm.
5. Biogen Idec news and media. http://www.biogenidec.com/site/news-and- media.html.
6. Elan Pharmaceuticals Inc. 2006. TYSABRI(R) maintained remission in patients with moderate-to-severe Crohn's disease treated for longer than two years according to data presented this week. October 24, 2006. http://www.elan.com/News/2006/20061024.asp.